Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Moderna Inc (MRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,297,220
  • Shares Outstanding, K 329,000
  • Annual Sales, $ 135,070 K
  • Annual Income, $ -384,730 K
  • 60-Month Beta N/A
  • Price/Sales 53.15
  • Price/Cash Flow N/A
  • Price/Book 4.69
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/06/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.45
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.88 +10.96%
on 02/21/19
24.40 -14.14%
on 02/26/19
+0.12 (+0.58%)
since 02/19/19
3-Month
13.03 +60.78%
on 12/26/18
24.40 -14.14%
on 02/26/19
+4.77 (+29.48%)
since 12/19/18

Most Recent Stories

More News
Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress

--Ends Year With $1.7 Billion in Cash, Cash Equivalents and Investments

MRNA : 20.82 (-6.13%)
Moderna to Present at Upcoming Investor Conferences in March

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today...

MRNA : 20.82 (-6.13%)
Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3

--Company plans to advance mRNA-1653 into a Phase 1b study in seropositive pediatric subjects

MRNA : 20.82 (-6.13%)
Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today...

MRNA : 20.82 (-6.13%)
Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,...

MRNA : 20.82 (-6.13%)
Moderna (MRNA) Announces Pipeline Progress, Shares Rise

Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.

AZN : 42.85 (+0.63%)
MRK : 81.72 (+0.45%)
VRTX : 182.99 (-2.39%)
MRNA : 20.82 (-6.13%)
Why Clinical Trial Advantages and Regulatory Process in EU may Hold Advantages Over the U.S.

Financialnewsmedia.com News Commentary

LJPC : 7.23 (-0.82%)
MRNA : 20.82 (-6.13%)
PFE : 42.26 (+1.08%)
MBRX : 1.28 (+2.40%)
AXSM : 12.90 (+12.47%)
Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives

--IND amendment submitted to the FDA for a Phase 2 cohort of OX40L (mRNA-2416) to treat advanced ovarian carcinoma

MRNA : 20.82 (-6.13%)
Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,announced...

JPM : 107.93 (+0.69%)
MRNA : 20.82 (-6.13%)
Foghorn(R) Therapeutics appoints Carl P. Decicco, Ph.D. as Chief Scientific Officer

Foghorn(R) Therapeutics Inc. (Foghorn), a discoverer and developer of new medicines based on insights into genetic mutations in the chromatin regulatory system, and Flagship Pioneering, a...

SYRS : 8.84 (-1.34%)
MCRB : 6.67 (+1.52%)
EVLO : 8.55 (-1.38%)
MRK : 81.72 (+0.45%)
DNLI : 23.48 (-3.93%)
MRNA : 20.82 (-6.13%)
RUBY : 16.69 (-4.85%)
BMY : 49.90 (+0.08%)
Trade MRNA with:

Business Summary

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA-...

See More

Key Turning Points

2nd Resistance Point 22.87
1st Resistance Point 22.53
Last Price 20.82
1st Support Level 21.53
2nd Support Level 20.87

See More

52-Week High 24.40
Last Price 20.82
Fibonacci 61.8% 20.06
Fibonacci 50% 18.72
Fibonacci 38.2% 17.37
52-Week Low 13.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar